The introduction of bevacizumab with carboplatin taxol therapy for the treatment of non-small cell lung cancer has been highly successful and has increased survival in these patients. Although studies evaluating other anti-angiogenesis therapies that target the same pathway have been unsuccessful, the reasons for this are unclear. Prof Roman Perez-Soler outlines the potential for new anti-angiogenesis drugs which target alternative pathways. It is hoped that these agents can be used to successfully treat patients who experience unacceptable levels of adverse effects from bevacizumab.